Rhelion Life Sciences Corp.
RHEL
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -83.79% | -16.76% | -13.96% | 23.67% | -59.90% |
| Total Depreciation and Amortization | -6.38% | -14.06% | 3.04% | -9.80% | -53.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 179.36% | 97.96% | -15.56% | 8.20% | 707.92% |
| Change in Net Operating Assets | 520.13% | -491.93% | -87.96% | -52.97% | -68.80% |
| Cash from Operations | 42.30% | -4.57% | -88.60% | 23.84% | -189.49% |
| Capital Expenditure | 26.09% | -27.78% | 98.12% | -248.91% | 0.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 68.02% | 33.12% | -121.56% | -- | -100.00% |
| Cash from Investing | 67.59% | 32.77% | -36.60% | -802.55% | -17.09% |
| Total Debt Issued | -200.17% | -- | -100.00% | -78.51% | -- |
| Total Debt Repaid | -1.20% | 25.74% | 95.08% | -1,467.13% | 179.18% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -233.85% | 541.87% | 95.01% | -1,067.58% | 212.36% |
| Foreign Exchange rate Adjustments | 96.93% | -180.69% | -34.42% | -29.52% | 2,631.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.30% | 20.47% | 10.87% | -217.25% | -187.51% |